My Tiny Feed

theglobeandmail.com

Psychedelic Drugs: FDA Approvals and Future of Mental Health Treatment

The FDA approval of Cybin's synthetic psilocybin for phase 3 trials, and MindMed's upcoming LSD trials for anxiety, signify progress despite recent setbacks in the psychedelic drug development sector.

Read original article in English

English

Canada

HealthInvestmentMental HealthRegulationClinical TrialsPsychedelics

Cybin Inc.Mind Medicine (Mindmed) Inc.Lykos PharmaceuticalsMultidisciplinary Association For Psychedelic StudiesFda

Doug DrysdaleAndrew TsaiRick DoblinPaul GlavineElon Musk

What recent FDA approval has Cybin Inc. received and what is its purpose?: Cybin Inc. received FDA approval for phase 3 trials of its synthetic psilocybin for major depressive disorder, aiming for results in 2026. This follows setbacks for other psychedelic drug developers, such as Lykos Pharmaceuticals and Compass Pathways.
What are the plans of MindMed Inc. regarding clinical trials and what condition are they targeting?: MindMed Inc. also plans phase 3 trials this year using LSD to treat anxiety, expecting results in 2026. Both companies aim to address the significant unmet need for new mental health treatments.
What is the "functional unblinding" challenge in psychedelic drug trials, and how does it impact trial design?: A major concern in psychedelic drug trials is "functional unblinding," where patients with prior psychedelic experience can identify if they're receiving the drug or a placebo. This necessitates careful trial design to mitigate bias.
What are some of the major concerns and questions surrounding the commercial viability of psychedelic-based drugs?: The psychedelic renaissance has attracted substantial investment, with Cybin and MindMed raising significant funds. However, questions about patent protection, cost of administration, and the potential for misuse remain.
Despite recent setbacks, what is the overall outlook and potential of psychedelic drugs in treating mental health conditions?: Despite recent setbacks and lingering concerns, there's cautious optimism surrounding the potential for psychedelic-based treatments for mental health conditions given the large unmet need and significant investment.

Jan 23, 10:08

Trump Launches \$500 Billion AI Project to Cure Cancer

President Trump launched Project Stargate, a \$500 billion AI-driven initiative to develop personalized mRNA cancer vaccines, aiming to detect and treat early-stage cancers through AI-powered blood tests and rapid vaccine production within 48 hours, despite concerns about public and political resistance.

Jan 23, 01:10

Microplastics Linked to Brain Blood Clots, Raising Dementia and Stroke Risks

A Peking University study reveals microplastics in the brain trigger immune responses, causing blood clots that may lead to stroke, depression, and possibly dementia; further research is needed.

Jan 23, 01:10

Rare Gene Mutation Linked to Late-Onset Alzheimer's

A study of an Italian family with six members affected by late-onset Alzheimer's disease reveals a rare mutation in the GRIN2C gene as a probable cause, offering a significant advancement in understanding the disease's genetic basis.

Jan 23, 01:10

Danish Medical Data Breach Exposes 130,000 Patient Records

A data breach at a Danish medical practice group exposed the sensitive information of 130,000 patients, including names, addresses, national identification numbers, and treatment protocols, nearly a month after the initial cyberattack, sparking public outrage over the delayed notification.